The article "Non-communicable diseases, injuries, and mental ill-health in Africa: the role of the Africa Centres for Disease Control and Prevention" examines the role of the Africa CDC in addressing non-communicable diseases (NCDs), injuries, and mental health across the continent. It highlights ho...w Africa CDC, originally focused on communicable disease response, has expanded its mandate to include NCDs and mental health, driven by the high mortality and morbidity associated with these conditions.
more
As the nation’s public health leader, the Centers for Disease Control and Prevention (CDC) is actively engaged in a national effort to protect the public’s health from the harmful effects of climate change. Scientists from CDC’s National Center for Emerging and Zoonotic Infectious Diseases (NC...EZID) are at the forefront of many of these efforts. This report highlights some of that work and also looks ahead to the important work yet to come.
more
Employees, Coworkers, and Supervisors
Accessed: 20.11.2019
The Centers for Disease Control and Prevention (CDC) provide information about radiation emergencies for the public and professionals.
This annual report presents key highlights of our results and are a testament to our staff’s hard work and dedication to safeguarding Africa’s health. We are indebted to the continued support of the Chairperson of the African Union Commission, the Africa CDC Governing Board, and the Technical an...d Advisory Council of Africa CDC.
Overall, it has been another successful year for the Africa CDC, for Africa and health security in general. I am grateful for your ongoing support and
look forward to continuing to work with you in the years ahead.
more
The Event-based Surveillance Framework is intended to be used by authorities and agencies responsible for
surveillance and response. This framework serves as an outline to guide stakeholders interested in implementing
event-based surveillance (EBS) using a multisectoral, One Health approach. To ...that end, the document is arranged
in interlinked chapters and annexes that can be modified and adapted, as needed, by users.
This is a revised version of the original “Framework for Event-based Surveillance” that was published in 2018. This
framework does not replace any other available EBS materials, but rather builds on existing relevant or related
documents and serves as a practical guide for the implementation of EBS in Africa. This framework is aligned with
the third edition of the WHO Joint External Evaluation for the following indicators: strengthened early warning
surveillance systems that are able to detect events of significance for public health and health security (Indicator
D2.1); improved communication and collaboration across sectors and between National, intermediate and local
public health response levels of authority regarding surveillance of events of public health significance (Indicator
D2.2); and improved national and intermediate-level capacity to analyse data (Indicator D2.3). As countries begin
to implement and demonstrate EBS functionality they will ensure an increase in JEE scores and progress towards
meeting the requirements outlined in the IHR3F
Additionally, in African Union Member States that have adopted the Integrated Disease Surveillance and
Response (IDSR) strategy, this document is a complement to and can enhance the implementation of IDSR,
especially for the 3rd edition (2019) that includes components related to EBS.
more
ي الغرض من إطار عمل إجراءات المراقبة القائمة عىل األحداث هو أن به
ن
تستعي السلطات والوكاالت المسؤولة عن المراقبة
ُ واالستجابة. كما
تيب إرشال تعىل سبيل المثال؛ هذ...ه الوثيقة ألصحاب المصلحة
ي
ُ
ُعد بمثابة ك
ا عاما ي
إطار استخدام
ي
الذين يرغبون ف ن
نهج "صحة واحدة" متعدد القطاعات لتنفيذ المراقبة القائمة عىل األحداث . و للقيام بذلك، تشتمل الوثيقة عىل فصول وملحق
ن مرتبطة ويمكن
للمستخدمي تغييها وتحديثها
بناء عىل احتياجاتهم الخاصة.
ُعد هذه
الت ي وت نسخة منقحة من النسخة األصلية "إطار عمل المراقبة القائمة عىل األحداث"
عام
ي
ن صدرت
ف 2018 .و ال ينسخ إطار
العمل هذا أو يحل محل أي مواد أخرى متاحة حاليا في ما يتعلق بمج ال المراقبة القائمة عىل األحداث أن
ن ؛ وبدال من ذلك، ينبعي
يستند إطار العمل إل الوثائق الموجودة سابقا ذات الصلة أو مرتبطة وأن يكون تيب
ُ
ك ا إرشاديا عملي ا لتنفيذ المراقبة القائمة عىل
األحداث أفريقيا.
ي
ن
ف ويتوافق إطار العمل ك لمنظمة الصحة العالمية
المشي
ي
هذا مع الطبعة الثالثة من التقييم الخارج فيما يتعلق
ر بالمؤشات التالية: تعزيز
ي عىل كشف األحداث ذات األهمية للصحة العامة واألمن الصح أنظمة المراقبة و اإلنذار المبكر القادر ة
ر المؤش )
حسنة والتعاون عي القطاعات وبين 1.D2)؛ مستويات استجابة الصحة العمومية الوطنية والمتوسطة
ُ
وقنوات االتصال الم
العامة واألمن الصح والمحلية فيما يتعلق بمراقبة األحداث ذات األهمية للصحة
ي
ر )المؤش
ن 2.D2)؛ القدرة عىل
وتحسي تحليل
ن البيانات عىل المستوى المتوسط والوطت ي
ر )المؤش
رش 3.D2 .)باإلضافة إل وع
الدول تنفيذ و
ي
ن
ف عرض مهام ووظائف المراقبة
القائمة عىل األحداث إذ ، اللوائح الصحية
ي
درجات التقييم المشي ك وإحراز تقدم نحو تلبية المتطلبات المبينة ف ن
ي
ستضمن زيادة ف ن
الدولية
.
تحسين أيضا، تنفيذ المراقبة المتكاملة لألمراض واالستجابة لها، وذلك بالنسبة
ي
ن
تعد هذه الوثيقة مكملة ويمكن أن تساعد ف ل لدول
ا
ي
االتحاد األفريق
ي
ن
اعتمدت االسي األعضاء ف اتيجية المتكاملة لمراقبة األمراض واالستجابة لها،
لت عىل وجه الخصوص ي
بالنسبة
للطبعة الثالثة ) 2019 تتضمن أجزاء حول
( الت المراقبة القائمة عىل األحداث ي
.
more
Over the past weeks, there has been wide media attention on the risk of transmission of the novel coronavirus [severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)] by asymptomatic individuals. This situation has also been extensively discussed on various platforms globally. The purpose of t...his position statement is for the Africa Centres for Diseases Control and Prevention (Africa CDC) to clarify the situation of transmission of SARS-CoV-2 by pre-asymptomatic and asymptomatic Individuals.
more
This document provides guidance for African Union Member States on actions to be taken to ensure they continue to meet all the health
needs of their citizens in accordance with achieving the objectives of the Africa Health Strategy 2016 – 2030.
The Africa Centres for Disease Control and Prevention (Africa CDC) is concerned about inaccurate information being distributed through traditional and social media regarding prevention and treatment of novel coronavirus disease (COVID-19).
Africa Centers for Disease Control and Prevention (Africa CDC) is aware of the media releases of the preliminary results of a large randomized clinical trial conducted in the United Kingdom, which included dexamethasone, a corticosteroid, as one of the drugs used for the treatment of COVID-19 patien...ts. The investigators reported that administration of oral or injectable dexamethasone resulted in about one-third reduction in mortality among COVID-19 patientsi that required mechanical ventilation and about one-fifth for patients requiring oxygen.
more
Taking the whole of Africa approach to fighting the COVID-19 pandemic has and will continue to require coordinated efforts from multiple stakeholders from across the continent. Africa CDC would like to acknowledge the deep partnership and continued support of AUDA-NEPAD, AVAREF, WHO AFRO, the Bill a...nd Melinda Gates Foundation and the Mastercard Foundation. These partners have helped to shape and drive the continent’s strategic response to the COVID-19 pandemic and have offered support to ensure the continent receives a fair and equitable share of the COVID-19 vaccine without delay.
We look forward to continuing and deepening our partnership for the benefit of the public health of Africa.
more
AstraZeneca-SKBio in South Korea and Serum Institute of India
Ivermectin is an antiparasitic drug approved for the treatment of parasitic infections, including strongyloidiasis and onchocerciasis in humans. There is a reported increase in the use of ivermectin for the prevention and treatment of COVID-19 by the public in African Union Member States.
Currently..., there is:
1. No scientific evidence from pre-clinical studies on the therapeutic effect of ivermectin for the management of COVID-19;
2. No evidence of its clinical efficacy for the management of patients with asymptomatic, mild, moderate or severe COVID-19; and
3. No safety data regarding the use of ivermectin for COVID-19 in the majority of the published studies.
more
Limited coverage of laboratory services and long turnaround times from real-time reverse transcription-polymerase chain reaction (rRT-PCR) for the detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has been insufficient to meet the demands in many African countries in response... to the COVID-19 pandemic. Rapid antigen diagnostic tests (AgRDTs) are potentially useful as they can inform healthcare workers and individuals of their infection status at point-of-care testing
more
The purpose of this document is to provide guidance on the use of pooled sample testing strategy in coronavirus disease (COVID-19)
testing laboratories of the African Union Member States for scaling up SARS-CoV-2 nucleic acid testing capacity with the available resources. The current document descr...ibes the effect of factors such as the prevalence of COVID-19 in the population to be tested, the homogeneity of pools, and the sensitivity of the molecular test in optimal pool size determination. It also highlights the importance of monitoring the prevalence of COVID-19 in a population to be tested and proper validation of the test, to limit the potential for false-negative results. Validation studies to determine the optimal pool size by testing laboratories are recommended as the optimum approach. A safe, simple ‘two-stage pooling’ option has been indicated in this guidance to be used by laboratories until such validation can be achieved.
more
Available in English, French, Portuguese and Arabic
Successful immunization of a critical mass of the African population with one or several safe and efficacious COVID-19 vaccines.Key objectives1. Accelerate African involvement in the clinical development of a vaccine. 2. Ensur...e African countries can access a sufficient share of the global vaccine supply.3. Remove barriers to widespread delivery and uptake of effective vaccines across Africa.
more
It is intended for use among clinicians taking care of moderate to severe COVID-19 cases.
The COVID-19 outbreak has brought with it the need for improved critical care for patients who develop severe disease. The majority of COVID-19 patients present with mild to moderate illness, 15% develop sever...e illness and about 5% develop critical conditions needing intensive care unit (ICU) care, requiring noninvasive or invasive ventilation
more